Cargando…

Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Deletion but Not Inhibition of Extracellular PCSK9 Reduces Infarct Sizes Ex Vivo but Not In Vivo

Hypoxia upregulates PCSK9 expression in the heart, and PCSK9 affects the function of myocytes. This study aimed to investigate the impact of PCSK9 on reperfusion injury in rats and mice fed normal or high-fat diets. Either the genetic knockout of PCSK9 (mice) or the antagonism of circulating PCSK9 v...

Descripción completa

Detalles Bibliográficos
Autores principales: Schreckenberg, Rolf, Wolf, Annemarie, Szabados, Tamara, Gömöri, Kamilla, Szabó, István Adorján, Ágoston, Gergely, Brenner, Gábor, Bencsik, Péter, Ferdinandy, Péter, Schulz, Rainer, Schlüter, Klaus-Dieter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9223354/
https://www.ncbi.nlm.nih.gov/pubmed/35742954
http://dx.doi.org/10.3390/ijms23126512
_version_ 1784733105959993344
author Schreckenberg, Rolf
Wolf, Annemarie
Szabados, Tamara
Gömöri, Kamilla
Szabó, István Adorján
Ágoston, Gergely
Brenner, Gábor
Bencsik, Péter
Ferdinandy, Péter
Schulz, Rainer
Schlüter, Klaus-Dieter
author_facet Schreckenberg, Rolf
Wolf, Annemarie
Szabados, Tamara
Gömöri, Kamilla
Szabó, István Adorján
Ágoston, Gergely
Brenner, Gábor
Bencsik, Péter
Ferdinandy, Péter
Schulz, Rainer
Schlüter, Klaus-Dieter
author_sort Schreckenberg, Rolf
collection PubMed
description Hypoxia upregulates PCSK9 expression in the heart, and PCSK9 affects the function of myocytes. This study aimed to investigate the impact of PCSK9 on reperfusion injury in rats and mice fed normal or high-fat diets. Either the genetic knockout of PCSK9 (mice) or the antagonism of circulating PCSK9 via Pep2-8 (mice and rats) was used. Isolated perfused hearts were exposed to 45 min of ischemia followed by 120 min of reperfusion. In vivo, mice were fed normal or high-fat diets (2% cholesterol) for eight weeks prior to coronary artery occlusion (45 min of ischemia) and reperfusion (120 min). Ischemia/reperfusion upregulates PCSK9 expression (rats and mice) and releases it into the perfusate. The inhibition of extracellular PCSK9 does not affect infarct sizes or functional recovery. However, genetic deletion largely reduces infarct size and improves post-ischemic recovery in mice ex vivo but not in vivo. A high-fat diet reduced the survival rate during ischemia and reperfusion, but in a PCSK9-independent manner that was associated with increased plasma matrix metalloproteinase (MMP)9 activity. PCSK9 deletion, but not the inhibition of extracellular PCSK9, reduces infarct sizes in ex vivo hearts, but this effect is overridden in vivo by factors such as MMP9.
format Online
Article
Text
id pubmed-9223354
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92233542022-06-24 Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Deletion but Not Inhibition of Extracellular PCSK9 Reduces Infarct Sizes Ex Vivo but Not In Vivo Schreckenberg, Rolf Wolf, Annemarie Szabados, Tamara Gömöri, Kamilla Szabó, István Adorján Ágoston, Gergely Brenner, Gábor Bencsik, Péter Ferdinandy, Péter Schulz, Rainer Schlüter, Klaus-Dieter Int J Mol Sci Article Hypoxia upregulates PCSK9 expression in the heart, and PCSK9 affects the function of myocytes. This study aimed to investigate the impact of PCSK9 on reperfusion injury in rats and mice fed normal or high-fat diets. Either the genetic knockout of PCSK9 (mice) or the antagonism of circulating PCSK9 via Pep2-8 (mice and rats) was used. Isolated perfused hearts were exposed to 45 min of ischemia followed by 120 min of reperfusion. In vivo, mice were fed normal or high-fat diets (2% cholesterol) for eight weeks prior to coronary artery occlusion (45 min of ischemia) and reperfusion (120 min). Ischemia/reperfusion upregulates PCSK9 expression (rats and mice) and releases it into the perfusate. The inhibition of extracellular PCSK9 does not affect infarct sizes or functional recovery. However, genetic deletion largely reduces infarct size and improves post-ischemic recovery in mice ex vivo but not in vivo. A high-fat diet reduced the survival rate during ischemia and reperfusion, but in a PCSK9-independent manner that was associated with increased plasma matrix metalloproteinase (MMP)9 activity. PCSK9 deletion, but not the inhibition of extracellular PCSK9, reduces infarct sizes in ex vivo hearts, but this effect is overridden in vivo by factors such as MMP9. MDPI 2022-06-10 /pmc/articles/PMC9223354/ /pubmed/35742954 http://dx.doi.org/10.3390/ijms23126512 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Schreckenberg, Rolf
Wolf, Annemarie
Szabados, Tamara
Gömöri, Kamilla
Szabó, István Adorján
Ágoston, Gergely
Brenner, Gábor
Bencsik, Péter
Ferdinandy, Péter
Schulz, Rainer
Schlüter, Klaus-Dieter
Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Deletion but Not Inhibition of Extracellular PCSK9 Reduces Infarct Sizes Ex Vivo but Not In Vivo
title Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Deletion but Not Inhibition of Extracellular PCSK9 Reduces Infarct Sizes Ex Vivo but Not In Vivo
title_full Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Deletion but Not Inhibition of Extracellular PCSK9 Reduces Infarct Sizes Ex Vivo but Not In Vivo
title_fullStr Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Deletion but Not Inhibition of Extracellular PCSK9 Reduces Infarct Sizes Ex Vivo but Not In Vivo
title_full_unstemmed Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Deletion but Not Inhibition of Extracellular PCSK9 Reduces Infarct Sizes Ex Vivo but Not In Vivo
title_short Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Deletion but Not Inhibition of Extracellular PCSK9 Reduces Infarct Sizes Ex Vivo but Not In Vivo
title_sort proprotein convertase subtilisin kexin type 9 (pcsk9) deletion but not inhibition of extracellular pcsk9 reduces infarct sizes ex vivo but not in vivo
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9223354/
https://www.ncbi.nlm.nih.gov/pubmed/35742954
http://dx.doi.org/10.3390/ijms23126512
work_keys_str_mv AT schreckenbergrolf proproteinconvertasesubtilisinkexintype9pcsk9deletionbutnotinhibitionofextracellularpcsk9reducesinfarctsizesexvivobutnotinvivo
AT wolfannemarie proproteinconvertasesubtilisinkexintype9pcsk9deletionbutnotinhibitionofextracellularpcsk9reducesinfarctsizesexvivobutnotinvivo
AT szabadostamara proproteinconvertasesubtilisinkexintype9pcsk9deletionbutnotinhibitionofextracellularpcsk9reducesinfarctsizesexvivobutnotinvivo
AT gomorikamilla proproteinconvertasesubtilisinkexintype9pcsk9deletionbutnotinhibitionofextracellularpcsk9reducesinfarctsizesexvivobutnotinvivo
AT szaboistvanadorjan proproteinconvertasesubtilisinkexintype9pcsk9deletionbutnotinhibitionofextracellularpcsk9reducesinfarctsizesexvivobutnotinvivo
AT agostongergely proproteinconvertasesubtilisinkexintype9pcsk9deletionbutnotinhibitionofextracellularpcsk9reducesinfarctsizesexvivobutnotinvivo
AT brennergabor proproteinconvertasesubtilisinkexintype9pcsk9deletionbutnotinhibitionofextracellularpcsk9reducesinfarctsizesexvivobutnotinvivo
AT bencsikpeter proproteinconvertasesubtilisinkexintype9pcsk9deletionbutnotinhibitionofextracellularpcsk9reducesinfarctsizesexvivobutnotinvivo
AT ferdinandypeter proproteinconvertasesubtilisinkexintype9pcsk9deletionbutnotinhibitionofextracellularpcsk9reducesinfarctsizesexvivobutnotinvivo
AT schulzrainer proproteinconvertasesubtilisinkexintype9pcsk9deletionbutnotinhibitionofextracellularpcsk9reducesinfarctsizesexvivobutnotinvivo
AT schluterklausdieter proproteinconvertasesubtilisinkexintype9pcsk9deletionbutnotinhibitionofextracellularpcsk9reducesinfarctsizesexvivobutnotinvivo